Q-omics provides the consensus-scored PROCA1 profile across patient tissues and cancer cell-line models. PROCA1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, PROCA1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, PROCA1 RNA expression shows 18,926 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, and UVM as cancer lineages where PROCA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROCA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROCA1 survival associations across molecular data types. PROCA1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROCA1 RNA expression–survival associations across cancer types. High PROCA1 expression shows unfavorable associations in COAD, KIRC, UVM and LIHC, but favorable associations in HNSC and SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for PROCA1 RNA expression.
This table summarizes PROCA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PROCA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROCA1 shows higher tumor expression in COAD, LIHC, BLCA, STAD, HNSC and THCA. The COAD box plot shows higher PROCA1 RNA expression in tumor versus normal tissue (log2 FC = +0.411, t-test p < 0.001).
This table shows molecular features associated with PROCA1 in patient tissues and cancer cell lines. In patient samples, PROCA1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PROCA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
